223
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Establishment of reference interval for the tumour marker serum CYFRA 21-1 in healthy Chinese Han ethnic adults

, , , , , & show all
Pages 171-174 | Received 28 Mar 2017, Accepted 07 Jan 2018, Published online: 16 Jan 2018

References

  • Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.
  • Zhang ZH, Han YW, Liang H, et al. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med. 2015;4:1633–1638.
  • Kuang LI, Song WJ, Qing HM, et al. CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis. Genet Mol Res. 2015;14:3921–3931.
  • Huang YL, Chen J, Yan W, et al. Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis. Tumor Biol. 2015;36: 3137–3145.
  • Cui C, Sun X, Zhang J, et al. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. J Can Res Ther . 2014;10(Suppl): C131–C134.
  • Wang YX, Hu D, Yan X. Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2013;17:2383–2389.
  • Gu P, Huang G, Chen Y, et al. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398–405.
  • Song XM, Wang ZJ, Cao WJ, et al. The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects. Int J Clin Oncol. 2016;21: 1038–1045.
  • Barak V, Meirovitz A, Leibovici V, et al. The diagnostic and prognostic value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res. 2015; 35:5519–5524.
  • Xu Y, Xu L, Qiu M, et al. Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer. Sci Rep. 2015;5:9444.
  • Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90:2097–2105.
  • Piao X, Kong TW, Chang SJ, et al. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases. Gynecol Oncol. 2015;138:89–93.
  • CLSI and IFCC. C28-A3 document; Defining, establishing and verifying reference intervals in the clinical laboratory: approved guideline-third edition, 2008;28:1–76.
  • Yang J, Tang A, Zhang S, et al. The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male. J Clin Lab Anal. 2017;31:e22062.
  • Yang J, Sa M, Huang M, et al. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay. Clin Biochem. 2013;46:1705–1708.
  • Qin X, Lin L, Mo Z, et al. Reference intervals for serum alpha-fetoprotein and carcinoembryonic antigen in Chinese Han ethnic males from the Fangchenggang Area Male Health and Examination Survey. Int J Biol Markers. 2011;26:65–71.
  • Yang S, Qiao R, Li Z, et al. Establishment of reference intervals of 24 chemistries in apparently healthy adult Han population of Northern China. Clin Biochem. 2012;45:1213–1218.
  • Woo HY, Kim YJ, Park H. Establishment of reference intervals of tumor markers in Korean adults. Korean J Lab Med. 2008; 28:179–184.
  • Falzarano R, Viggiani V, Michienzi S, et al. Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers. Tumor Biol . 2013;34:3093–3100.
  • Patel JL, Erickson JA, Roberts WL, et al. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum. Clin Biochem. 2010;43:1449–1452.
  • Shi Q, Pu CQ, Wu WP, et al. The determination of medical reference values for tumor markers in cerebrospinal fluid. Zhonghua Yi Xue Za Zhi. 2009;89:355–356.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.